Restructuring, Impairment, and Related Charges (Tables)

12 Months Ended

Mar. 31, 2021

Restructuring and Related Activities [Abstract]

Summary of details for charges recorded

Restructuring, impairment, and related charges, net for the year ended March 31, 2021 consisted of the following:

	Year Ended March 31, 2021
(In millions)	U.S. Pharmaceutical		International (1)		Medical-Surgical Solutions		Prescription Technology Solutions		Corporate (2)		Total
Severance and employee-related costs, net	$	10	$	22	$	(1)	$	4	$	69	$	104
Exit and other-related costs (3)	11		17		4		—		27		59
Asset impairments and accelerated depreciation	—		46		1		—		9		56
Total	$	21	$	85	$	4	$	4	$	105	$	219

(1)Primarily represents costs associated with the operating model and cost optimization efforts described above.

(2)Represents costs associated with the operating model cost optimization efforts and the relocation of the Company’s headquarters described above in addition to various other initiatives.

(3)Exit and other-related costs primarily include project consulting fees.

Fiscal 2020

Restructuring, impairment, and related charges, net for the year ended March 31, 2020 consisted of the following:

	Year Ended March 31, 2020
(In millions)	U.S. Pharmaceutical (1)		International (2)		Medical-Surgical Solutions (3)		Prescription Technology Solutions		Corporate (4)		Total
Severance and employee-related costs, net	$	12	$	2	$	4	$	(1)	$	30	$	47
Exit and other-related costs (5)	1		13		19		—		46		79
Asset impairments and accelerated depreciation	10		6		1		—		13		30
Total	$	23	$	21	$	24	$	(1)	$	89	$	156

(1)Represents costs associated with dispositions and costs related to the relocation of the Company’s corporate headquarters described above.

(2)Primarily represents costs associated with the operating model and cost optimization efforts described above.

(3)Primarily represents costs associated with the growth initiative described above.

(4)Represents costs associated with the growth initiative, operating model cost optimization efforts, and with the relocation of the Company’s corporate headquarters described above.

(5)Exit and other-related costs primarily include project consulting fees.

Fiscal 2019

Restructuring, impairment, and related charges, net for the year ended March 31, 2019 consisted of the following:

	Year Ended March 31, 2019
(In millions)	U.S. Pharmaceutical (1)		International (2)		Medical-Surgical Solutions (3)		Prescription Technology Solutions		Corporate (4)		Total
Severance and employee-related costs, net	$	46	$	51	$	18	$	3	$	36	$	154
Exit and other-related costs (5)	9		83		20		—		52		164
Asset impairments and accelerated depreciation	6		24		3		—		1		34
Total	$	61	$	158	$	41	$	3	$	89	$	352

(1)Represents costs associated with the operating model cost optimization efforts and growth initiative described above.

(2)Primarily represents costs associated with the operating model cost optimization efforts and U.K. restructuring initiative focusing on underperforming retail pharmacy stores described above.

(3)Primarily represents costs associated with the growth initiative described above.

(4)Represents costs associated with operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above.

(5)Exit and other-related costs primarily include lease and other contract exit costs associated with closures of facilities and retail pharmacy stores as well as project consulting fees.

The following table summarizes the activity related to the restructuring liabilities associated with the Company’s restructuring initiatives for the years ended March 31, 2021 and 2020:

(In millions)	U.S. Pharmaceutical		International		Medical-Surgical Solutions		Prescription Technology Solutions		Corporate		Total
Balance, March 31, 2019	$	35	$	129	$	26	$	3	$	44	$	237
Restructuring, impairment, and related charges	23		21		24		(1)		89		156
Non-cash charges	(10)		(6)		(1)		—		(13)		(30)
Cash payments	(15)		(45)		(26)		(1)		(61)		(148)
Other	(4)		(33)		(1)		—		(20)		(58)
Balance, March 31, 2020 (1)	29		66		22		1		39		157
Restructuring, impairment, and related charges	21		85		4		4		105		219
Non-cash charges	—		(46)		(1)		—		(9)		(56)
Cash payments	(31)		(31)		(21)		(1)		(75)		(159)
Other	—		(8)		(1)		—		(1)		(10)
Balance, March 31, 2021 (2)	$	19	$	66	$	3	$	4	$	59	$	151

(1)    As of March 31, 2020, the total reserve balance was $157 million of which $118 million was recorded in Other accrued liabilities and $39 million was recorded in Other non-current liabilities.

(2)    As of March 31, 2021, the total reserve balance was $151 million of which $99 million was recorded in Other accrued liabilities and $52 million was recorded in Other non-current liabilities.